Ingenol disoxate

Drug Profile

Ingenol disoxate

Alternative Names: LEO-43204

Latest Information Update: 02 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator LEO Pharma
  • Class Antiacnes; Antineoplastics; Carboxylic acids; Cyclopropanes; Esters; Isoxazoles; Small molecules
  • Mechanism of Action Apoptosis stimulants; Protein kinase C stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Actinic keratosis; Squamous cell cancer
  • Phase II Acne vulgaris

Most Recent Events

  • 16 Jun 2017 Phase-III clinical trials in Squamous cell cancer (Prevention, Second-line therapy or greater, In adolescents, In adults, In children, In the elderly) in United Kingdom, Spain, Italy, Germany, France, Canada, USA (Topical) (EudraCT2017-000228-85) (NCT03115476)
  • 19 Apr 2017 LEO Pharma plans a phase III trial for Squamous cell cancer (Prevention, Second-line therapy or greater, In children, In adolescents, In adults, In elderly) in USA (NCT03115476)
  • 01 Apr 2017 LEO Pharma completes a phase II trial in Acne vulgaris in USA (Topical) (NCT02575950)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top